Symposium Provides New Insights on Immunotherapy for Cancer

For immediate release
January 22, 2018
Contact
Alise Fisher
571-483-1354
alise.fisher@asco.org

SAN FRANCISCO - Eight noteworthy studies exploring the implications of immuno-oncology for patient care will be presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place January 25-27 at the San Francisco Marriott Marquis in San Francisco, California. These notable abstracts discuss the efficacy of immunotherapy in rare cancers, biomarkers to predict which patients will benefit most, and managing the adverse effects of immune-based treatments.

Experts in immuno-oncology are available to comment on the studies below.

Abstract 25: Genomic biomarkers in relation to PD-1 checkpoint blockade response.

Poster Session B
Friday, January 26, 2018: 11:30 a.m. - 1:00 p.m. PT
Friday, January 26, 2018: 5:30 p.m. - 6:30 p.m. PT
Golden Gate Hall, B2 Level
Tanguy Y. Seiwert, MD
University of Chicago
Chicago, IL

Abstract 51: IFN? mRNA signature (IFN? sig), circulating tumor DNA (ctDNA), and survival in NSCLC or urothelial cancer (UC) treated with durvalumab (D).

Published on ASCO (https://www.asco.org)

Home > Symposium Provides New Insights on Immunotherapy for Cancer
**Poster Session A**
Thursday, January 25, 2018: 11:30 a.m. - 1:00 p.m. PT
Thursday, January 25, 2018: 5:30 p.m. - 6:30 p.m. PT
Golden Gate Hall, B2 Level
Brandon W. Higgs, PhD
MedImmune
Gaithersburg, MD

**Abstract 63:** HIV-positive Kaposi sarcoma and immune checkpoint blockade.

**Poster Session A**
Thursday, January 25, 2018: 11:30 a.m. - 1:00 p.m. PT
Thursday, January 25, 2018: 5:30 p.m. - 6:30 p.m. PT
Golden Gate Hall, B2 Level
Natalie Galanina, MD
University of California San Diego Moores Cancer Center
San Diego, CA

**Abstract 103:** Exploration of the cGAS-STING pathway in prostate cancer.

**Oral Abstract Session C**
Saturday, January 27, 2018: 10:45 a.m. - 10:54 a.m. PT
Yerba Buena Ballroom, Salon 9, Lower B2 Level
Emma Reilly
Almac Diagnostics
Craigavon, United Kingdom

**Abstract 120:** High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.

**Oral Abstract Session B**
Friday, January 26, 2018: 1:55 p.m. - 2:04 p.m. PT
Yerba Buena Ballroom, Salon 9, Lower B2 Level
Jeremy S. Abramson, MD
Massachusetts General Hospital Cancer Center
Boston, MA
Abstract 127: Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?

Poster Session A
Thursday, January 25, 2018: 11:30 a.m. - 1:00 p.m. PT
Thursday, January 25, 2018: 5:30 p.m. - 6:30 p.m. PT
Golden Gate Hall, B2 Level
Kerry Lynn Reynolds, MD
Massachusetts General Hospital
Boston, MA


Poster Session B
Friday, January 26, 2018: 11:30 a.m. - 1:00 p.m. PT
Friday, January 26, 2018: 5:30 p.m. - 6:30 p.m. PT
Golden Gate Hall, B2 Level
Limo Chen
The University of Texas MD Anderson Cancer Center
Houston, TX

Abstract 192: 18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

Poster Session A
Thursday, January 25, 2018: 11:30 a.m. - 1:00 p.m. PT
Thursday, January 25, 2018: 5:30 p.m. - 6:30 p.m. PT
Golden Gate Hall, B2 Level
Sandra P. D'Angelo, MD
Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College
New York, NY

2018 ASCO-SITC Clinical Immuno-Oncology Symposium News Planning Team:
Michael S. Sabel, MD, FACS, American Society of Clinical Oncology (ASCO); Mario Sznol, MD, American Society of Clinical Oncology (ASCO) and Society for Immunotherapy of Cancer (SITC).

View the disclosures for the News Planning Team.

ATTRIBUTION TO THE 2018 ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE.
About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.

About the Society for Immunotherapy of Cancer:

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.

Learn more about SITC, its educational offerings and other resources.